In brief
Fertility blood tests answer particular questions about hormones, ovarian reserve or health relevant to reproductive care. They do not provide one overall fertility score, measure every stage of conception or guarantee future pregnancy. The useful starting point is what you want to understand and what a result could change.
This guide separates the tests, their timing and their limits. It is for people learning about their reproductive health, planning ahead, trying to conceive, considering preservation or preparing for treatment. Blood testing can be appropriate before a fertility difficulty develops, but it should have a purpose; not everyone needs a panel.
We refer to ovaries, testes and the relevant hormone pathways rather than assuming a particular relationship or identity. Your organs, medicines, hormone treatment and role in family building determine the useful assessment. Men have their own endocrine and reproductive questions; their assessment is not merely an addition to someone else’s.
Key takeaways
- Choose the question before the panel: ovulation, ovarian response, symptoms and sperm production are different questions.
- Timing is part of the test. A day-21 progesterone sample is a mid-luteal example for a 28-day cycle, not a universal appointment date.
- AMH is not an egg-quality score or a prediction of spontaneous pregnancy.
- Blood hormone results do not replace semen analysis, tubal assessment or pelvic imaging when those are relevant.
- A result needs its units, laboratory interval, collection date, cycle context and medicines.
- Agree who will explain the result, whether anything needs repeating and what the next decision will be.
Start with the question you want answered
A useful request can be as simple as “I want to understand whether my cycle pattern needs assessment”, “I am considering egg freezing”, or “I have symptoms that might be hormonal”. You do not have to describe yourself as infertile or be trying for a baby to ask those questions. Education alone may be enough for your current goal.
Before testing, write down the decision you want help with. Would the result change a treatment timetable, prompt a clinical assessment, clarify collection timing or help you consider preservation? If neither you nor the provider can explain what would change, a larger panel may add uncertainty rather than useful information.
A test should also have an interpretation plan. Establish who will receive the report, how an unexpected result is handled and how you can ask questions. The word “normal” on a portal is useful information about a measurement, but it is not an explanation of every reproductive question.
Where blood tests fit in the Fertility Dance
Conception involves linked processes: hormonal signalling and ovulation, eggs, sperm, transport through the reproductive tract, fertilisation, the uterus and implantation, then pregnancy maintenance. Blood tests mostly inform the signalling and health parts of that sequence. Some markers also help plan the ovaries’ response to stimulation.
Think of the assessment as a map. Hormone measurements describe particular signals; semen analysis examines a sperm sample; imaging and tubal tests examine structures or passage. None can stand in for all the others. A reassuring hormone result should remain reassuring about what it measured.
When conception is unresolved, the next question is which relevant part of the map has not yet been assessed, not which increasingly large panel can be purchased. A deeper investigation may be appropriate, but it cannot be promised to reveal a cause.
Common fertility blood tests: the question-to-test map
This is an educational map, not a checklist of tests everyone should order. A clinician selects the useful measurements in light of your goal and history.
| Measurement | Useful question | Important limit |
|---|---|---|
| Progesterone | Is there evidence of recent ovulation? | Collection timing matters; one value does not grade the whole luteal phase. |
| AMH | What might ovarian response to stimulation look like? | Not an egg-quality measurement or spontaneous-pregnancy forecast. |
| FSH with estradiol | How do early-cycle ovarian and pituitary signals fit together? | A phase-specific interpretation, not a stand-alone fertility score. |
| LH | What does the hormonal signalling pattern suggest? | A blood value is different from detecting a urine LH surge. |
| TSH and selected thyroid hormones | Could thyroid disease be relevant to symptoms or care? | Not everyone needs every thyroid measurement. |
| Prolactin | Could a raised hormone be relevant to particular symptoms or ovulatory problems? | Not a universal infertility screening test. |
| Testosterone and selected gonadotrophins in men | Is endocrine assessment relevant to symptoms or sperm findings? | A blood testosterone result does not measure sperm count. |
| Other health or treatment-preparation tests | Are there specific health or safety questions before pregnancy or treatment? | Not interchangeable with a fertility hormone panel. |
Progesterone: evidence of ovulation, with timing attached
After ovulation, the follicle becomes the corpus luteum, which produces progesterone. In a natural menstrual cycle, a blood measurement taken at the appropriate point can help establish evidence of recent ovulation. The question is about that cycle; it is not a lifetime certificate of ovulation or fertility.
The commonly used “day-21 test” refers to the mid-luteal phase in a 28-day cycle. Gloucestershire Hospitals’ current collection instructions specify seven days before the next predicted period. In a predictable 35-day cycle, that arithmetic gives approximately day 28. With variable cycles, a date calculated from the previous month may not fit this month.
A low result needs the collection context before a conclusion. Was the sample taken before ovulation, at the intended point after it, or near the next bleed? The laboratory notes that a lower value does not exclude an ovulatory cycle. Do not treat an early sample as proof of failed ovulation.
Progesterone secretion fluctuates. ASRM’s 2021 opinion distinguishes evidence of ovulation from assessing luteal quality: a single level cannot reliably answer the latter. Prescribed progesterone and fertility treatment create additional interpretation issues; do not use natural-cycle advice to alter a treatment regimen.
Cycle timing: early-cycle, mid-luteal and any-cycle questions
Use the ordering clinician’s and laboratory’s instructions. Different purposes can require different timing, including monitoring during fertility treatment.
| Test or purpose | Typical context | What to confirm |
|---|---|---|
| Basal FSH and estradiol | Early follicular phase; ASRM describes days 2–4 | How your provider defines day 1 and which day it requests. |
| Progesterone for ovulation | About seven days before the expected next period | Your actual cycle pattern and whether ovulation timing is known. |
| AMH | Can generally be measured on any cycle day | Hormonal medicines, assay and previous results if comparing. |
| Selected male hormone tests | Timing depends on the analyte and clinical purpose | Time-of-day and repeat-sampling instructions from the clinician. |
| Treatment monitoring | According to the treatment protocol | The treating clinic’s date, dose and collection instructions. |
AMH: ovarian reserve and stimulation planning
Anti-Müllerian hormone is associated with small ovarian follicles and is used in ovarian-reserve assessment. Its clearest clinical uses include anticipating response to ovarian stimulation, alongside other relevant information. It does not count every remaining egg, determine egg quality or provide a personal date by which pregnancy must happen.
NICE NG257, published in March 2026, advises against using AMH to predict clinical pregnancy through spontaneous conception. This limitation belongs beside the result rather than hidden in a disclaimer: a lower AMH must not be translated into “you cannot conceive naturally”.
For a preservation or IVF discussion, ask how AMH, age, ultrasound information and any previous stimulation response fit together. A value by itself cannot guarantee the number of eggs collected or the eventual outcome. When comparing tests, retain the original units, laboratory and medicines at each collection.
FSH and estradiol: interpret the pair and the phase
Follicle-stimulating hormone, or FSH, is a pituitary signal involved in follicle development. Estradiol is an oestrogen produced by developing follicles. For basal ovarian-reserve interpretation, the early-cycle values belong together: estradiol can affect how an FSH value is understood.
A result obtained during a different cycle phase cannot simply be compared with an early-follicular interval. Nor should two results be called an improvement or deterioration if their collection contexts differ. Ask what phase the laboratory interval describes and whether the intended baseline question was actually tested.
If periods are absent or markedly irregular, the clinician may be investigating the cause of that pattern rather than doing a routine early-cycle reserve check. Do not wait indefinitely for an imagined perfect sampling day or assume the same interpretation applies; agree a suitable assessment plan.
LH: a blood result and an ovulation predictor are different tools
Luteinising hormone, or LH, is another pituitary signal. A surge contributes to the ovulatory process, but a single blood LH measurement is a snapshot. It is not automatically evidence that an egg was released, and a laboratory blood panel is not the same thing as a sequence of urine ovulation-predictor tests.
For cycle questions, record whether you were tracking urine LH and what the test actually showed. An app’s predicted day is a calendar estimate, not a measured hormone event. If a clinician is investigating an irregular cycle, ask how LH is being used alongside symptoms and the other findings.
Avoid using an isolated LH value, or an LH-to-FSH comparison found online, to diagnose yourself. The appropriate assessment depends on the whole clinical question. Your next action should follow interpretation rather than an unsupervised attempt to change a number.
Thyroid testing: a health question with reproductive relevance
TSH is part of thyroid assessment. Additional thyroid measurements may be appropriate depending on the question and findings. Thyroid disease can be relevant to symptoms and reproductive care, but there is no rule that everyone needs every thyroid marker because they are curious about fertility.
Current NICE infertility-investigation guidance recommends thyroid-function testing where there are symptoms of thyroid disease. That recommendation concerns a clinical investigation pathway, not a restriction on asking about your health. A history of thyroid disease, current treatment or a particular symptom is worth discussing so the test request has a clear purpose.
A mildly out-of-range result is not proof of the reason for a fertility difficulty. Ask what it means in your circumstances, whether further thyroid assessment is needed and whether pregnancy or treatment planning changes the approach. Do not start or adjust thyroid medicine to meet an internet fertility target.
Prolactin: when a result needs context or a further laboratory check
Prolactin testing is not recommended as a blanket infertility screen. NICE restricts its use to particular clinical indications, such as an ovulatory disorder, galactorrhoea or a pituitary tumour. Galactorrhoea means unexpected milk discharge outside the relevant breastfeeding context; it is a symptom to discuss rather than diagnose from a panel.
A raised total prolactin result needs explanation. North West London Pathology describes macroprolactin, a larger form detected by some assays that can produce an apparent elevation without the same biological effect as the active form. The laboratory may investigate this where appropriate; local procedures differ.
Ask whether the finding needs confirmation, medication review or an additional laboratory assessment. Do not assume a flagged total value means a pituitary tumour or independently stop prescribed medicines. New significant symptoms require clinical assessment rather than repeated home sampling without a plan.
Men’s blood tests: hormones and sperm are related, not interchangeable
Men can seek reproductive education, preservation advice or assessment in their own right. Hormonal testing can be relevant when there are symptoms, examination findings or a semen result suggesting an endocrine question. AUA/ASRM’s male-infertility guideline, amended in 2024, supports selected endocrine assessment rather than indiscriminate testing.
FSH and testosterone may help investigate particular sperm-production or hormonal concerns; further tests depend on the findings. The result is interpreted alongside history, examination and semen analysis where relevant. A normal blood testosterone level cannot establish that sperm count, movement or shape are normal.
If you use prescribed testosterone, anabolic steroids or gender-affirming hormones, explain that clearly when discussing fertility goals. Do not start, stop or replace hormones from a blood result alone. Coordinate questions about sperm preservation or conception with the relevant prescriber and reproductive specialist.
A man planning years ahead may begin with learning rather than testing. A man with concerning symptoms or a severely abnormal semen finding may need prompt clinical assessment. These are different routes; neither should be reduced to buying the biggest available panel.
General health, screening and treatment-preparation tests
A blood test ordered before pregnancy or treatment may have a different purpose from a fertility hormone measurement. It might assess a health condition, infection-screening requirement or preparation for a procedure. Ask which question each item addresses and whether another test already answers it.
The NHS blood-tests information explains that tests are selected for symptoms, conditions and medicines, and that preparation can vary. A full blood count, for example, measures blood cells; it does not provide an ovarian-reserve or sperm-quality result. General health matters, but the labels should remain clear.
Fertility clinics can require their own screening, sample types and validity periods before donor treatment, storage or assisted conception. Do not assume a consumer hormone panel fulfils those requirements. Confirm the intended clinic’s requirements before collecting a sample specifically for treatment preparation.
Before collection: a practical preparation checklist
Confirm the names of the tests, intended collection date and sample method. Ask whether fasting, a particular time of day or another preparation is needed; do not impose a universal fasting rule on all fertility tests. If the booking date no longer matches your cycle, ask the provider how to adjust it.
Provide a current list of prescribed medicines, hormones and supplements, including doses where known. Laboratory interference and treatment effects can matter. Gloucestershire’s progesterone guidance has specific instructions for high-dose biotin; this illustrates why supplement details belong on the request, not why everyone should stop supplements by themselves.
If using a home kit, follow that kit’s collection, labelling, storage and dispatch instructions. Do not assume every marker is suitable for every collection method. For a clinic draw, tell the team about needle anxiety, fainting, access needs or difficulty with previous samples so the appointment can be planned constructively.
Keep a copy of the request and record collection date, approximate time, cycle day where relevant and any important context. Establish a way to check that the result arrived and who is responsible for explaining it. Testing is not complete simply because a sample was posted.
Read the report without turning it into a verdict
Start with five details: the actual analyte, value, unit, laboratory reference interval and collection context. The reference interval may be phase-specific or depend on the population and assay. “Outside range” means the measurement needs interpretation; it does not automatically diagnose a fertility barrier.
Do not compare numbers in different units as if they were the same scale. For AMH, for example, reports may use ng/mL or pmol/L. Keep the original reports and have the comparison checked rather than using an unexplained calculator or assuming a change proves accelerated reproductive ageing.
A laboratory reference interval, an ovulation-supporting decision value and a treatment-planning cut-off are different concepts. None is automatically a pregnancy-probability threshold. Ask what kind of comparison is being used and what clinical decision follows from it.
Reassuring findings do not need to be reframed as hidden problems. If your question has been answered and there is no unresolved symptom or decision, education or routine health care may be enough. If conception or treatment remains unresolved, map the remaining questions instead of dismissing the useful reassurance.
When repeating a test is useful—and when it is not
A repeat test should answer a named question: was timing unsuitable, does an unexpected result need confirmation, is a clinician monitoring a diagnosed condition, or is the result needed for a treatment decision? Repetition without a purpose can make natural variation look like a crisis.
Record what would change after the repeat. If the aim is to clarify a progesterone result, the collection plan must address cycle timing. If the aim is to monitor a condition or treatment, the responsible clinician should set the interval. There is no universal three-month rule for all reproductive blood tests.
Seek a more prompt conversation when there are absent or substantially changed periods, significant symptoms, a result the laboratory marks urgent, or an approaching medical-treatment or preservation deadline. Do not delay necessary specialist care while collecting a series of reassurance tests.
Match the assessment to your family-building role
In donor conception, reciprocal IVF or surrogacy, different people may contribute eggs, sperm or carry the pregnancy. The useful blood tests follow that role and the treatment plan. The person contributing eggs and the person carrying a pregnancy should not automatically receive identical panels.
ASRM’s fertility-evaluation guidance explicitly discusses donor-sperm, reciprocal-IVF and trans/non-binary pathways. Tell the team about relevant organs, surgery, hormone history and the route you are considering. Request explanations and appointment arrangements that respect your access needs and privacy.
When more than one person is being assessed, agree what information can be shared. Joint family-building decisions do not remove each person’s confidentiality or authority over their healthcare. A coordinated plan can connect the relevant findings without making one person responsible for everyone’s results.
Choose a next step matched to readiness
If you are learning, start with the related Library guides or free Frank and HerStory education. You do not need to buy testing to make your question valid. If you are considering a test, check what the current option measures, why it fits and how you will use the result.
For symptoms, a time-sensitive preservation question or a decision that needs clinical interpretation, a relevant standalone consultation may be the most useful route. The purpose is to select and connect appropriate assessment, not to presume a previous clinician missed a cause or make more testing inevitable.
Where several relevant factors need coordinated work, the six-month ProFertility Plan can support assessment, targeted investigations, clinical review, a tailored programme and reviews. It is an option for appropriate needs, not the default destination for every result. Treating clinicians retain responsibility for medicines and treatment decisions; necessary care must not be delayed.
Use this appointment checklist: What question does each test answer? Does timing change the interpretation? What information is reassuring? What remains unresolved? Would another investigation change care? Who owns the next action, and when will we review it?
Related guidance and support
Related blog articles
Frequently asked questions
Which blood test checks fertility?
There is no single overall fertility blood test. Progesterone, AMH and other selected hormones answer different questions; relevant semen, imaging or other assessment may also be needed.
Is day 21 the right day for everyone?
No. It is an example of mid-luteal sampling in a 28-day cycle. Agree timing for your actual cycle with the ordering clinician.
Can low progesterone prove I did not ovulate?
Not by itself. Collection timing, the laboratory’s interpretation and cycle context matter; a lower value does not exclude an ovulatory cycle.
Does AMH tell me my egg quality?
No. AMH informs ovarian-reserve and stimulation-response questions, not egg quality or a personal chance of spontaneous pregnancy.
Do men need fertility blood tests?
Sometimes. Selected hormone tests may help investigate symptoms or sperm findings; a blood testosterone result does not replace semen analysis.
Do I need to fast?
Follow the instructions for the actual requested tests. There is no universal fasting instruction for every fertility panel.
Can I test at home?
Some tests have suitable home collection options. Check the actual test, collection method, timing, dispatch instructions and interpretation support; do not assume every marker is appropriate for every kit.
Should I stop medication before testing?
Do not change prescribed medicines independently. Tell the provider about medicines, hormones and supplements and follow specific agreed instructions.
Can I ask about testing before trying for a baby?
Yes. Learning, future planning and preservation are valid reasons to ask. A test is useful when it answers a relevant question, not simply because a panel exists.
Do reassuring blood results guarantee pregnancy?
No. They are reassuring about what was measured, but blood tests do not examine every stage of conception or predict a guaranteed outcome.
Clinical sources
- NICE NG257: Investigation of fertility problems and management strategies; guideline published 31 March 2026. Current recommendations checked 14 October 2026.
- ASRM: Fertility evaluation of infertile women; committee opinion, 2021.
- ASRM: Testing and interpreting measures of ovarian reserve; committee opinion, 2020.
- Gloucestershire Hospitals: Progesterone; current pathology instructions accessed 14 October 2026. No publication date stated.
- NHS: Blood tests; reviewed 2 November 2023.
- NHS: Infertility diagnosis; current patient information accessed 14 October 2026.
- AUA/ASRM: Diagnosis and Treatment of Infertility in Men; guideline amended 2024.
- North West London Pathology: Macroprolactin investigations; updated 21 August 2025.
Source check: 2026-10-14. This guide is educational and does not replace individual medical advice.